Prime Medicine
Update in progressPRME (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Prime Medicine is a biotechnology company developing genetic medicines using Prime editing to treat diseases in the United States. Its lead candidate PM359 targets Chronic Granulomatous Disease in a Phase 1/2 trial; PM577 targets Wilson disease in preclinical studies; PM647 aims at SERPINA1-related liver disease. It also pursues liver and Cystic Fibrosis programs and offers Prime Editing tech. Collaborations include BMS, CF Foundation, Broad Institute, and Beam. Founded 2019, Cambridge, MA.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.16
- Governance
- -0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Allan Reine M.D.
- Founded2019
- Employees146
- Websiteprimemedicine.com
Identifiers
- ISINUS74168J1016
- FIGIBBG011RT3R55
- CUSIP74168J101
- CIK0001894562